CKD 0 3 0 3 B-chronic_disease
- 3 4 3 4 O
EPI 4 7 4 7 O
formula 8 15 8 15 O
will 16 20 16 20 O
be 21 23 21 23 O
used 24 28 24 28 O
for 29 32 29 32 O
adults 33 39 33 39 O

Current 0 7 40 47 O
treatment 8 17 48 57 B-treatment
with 18 22 58 62 I-treatment
a 23 24 63 64 I-treatment
separate 25 33 65 73 I-treatment
ascorbic 34 42 74 82 I-treatment
acid 43 47 83 87 I-treatment
preparation 48 59 88 99 I-treatment

Male 0 4 100 104 B-gender

Participation 0 13 105 118 O
in 14 16 119 121 O
any 17 20 122 125 O
interventional 21 35 126 140 O
study 36 41 141 146 O
of 42 44 147 149 O
another 45 52 150 157 O
investigational 53 68 158 173 B-treatment
product 69 76 174 181 I-treatment
, 76 77 181 182 O
biologic 78 86 183 191 B-treatment
, 86 87 191 192 O
device 88 94 193 199 O
, 94 95 199 200 O
or 96 98 201 203 O
other 99 104 204 209 O
agent 105 110 210 215 O
within 111 117 216 222 O
60 118 120 223 225 B-upper_bound
days 121 125 226 230 I-upper_bound
prior 126 131 231 236 I-upper_bound
to 132 134 237 239 O
the 135 138 240 243 O
first 139 144 244 249 O
dose 145 149 250 254 O
of 150 152 255 257 O
OC5 153 156 258 261 B-treatment
or 157 159 262 264 O
not 160 163 265 268 O
willing 164 171 269 276 O
to 172 174 277 279 O
forego 175 181 280 286 O
other 182 187 287 292 O
forms 188 193 293 298 O
of 194 196 299 301 O
investigational 197 212 302 317 B-treatment
treatment 213 222 318 327 I-treatment
during 223 229 328 334 O
this 230 234 335 339 O
study 235 240 340 345 O

Patients 0 8 346 354 O
receiving 9 18 355 364 O
vitamin 19 26 365 372 B-treatment
B6 27 29 373 375 I-treatment
must 30 34 376 380 O
be 35 37 381 383 O
receiving 38 47 384 393 O
a 48 49 394 395 O
stable 50 56 396 402 O
dose 57 61 403 407 O
for 62 65 408 411 O
at 66 68 412 414 O
least 69 74 415 420 O
3 75 76 421 422 B-lower_bound
months 77 83 423 429 I-lower_bound
prior 84 89 430 435 I-lower_bound
to 90 92 436 438 O
screening 93 102 439 448 O
and 103 106 449 452 O
must 107 111 453 457 O
not 112 115 458 461 O
change 116 122 462 468 O
the 123 126 469 472 O
dose 127 131 473 477 O
during 132 138 478 484 O
the 139 142 485 488 O
study 143 148 489 494 O

Patients 0 8 495 503 O
requiring 9 18 504 513 O
dialysis 19 27 514 522 B-treatment
or 28 30 523 525 O
at 31 33 526 528 O
immediate 34 43 529 538 O
risk 44 48 539 543 O
for 49 52 544 547 O
kidney 53 59 548 554 B-chronic_disease
failure 60 67 555 562 I-chronic_disease
or 68 70 563 565 O
expected 71 79 566 574 O
to 80 82 575 577 O
be 83 85 578 580 O
in 86 88 581 583 O
need 89 93 584 588 O
of 94 96 589 591 O
dialysis 97 105 592 600 O
during 106 112 601 607 O
the 113 116 608 611 O
study 117 122 612 617 O
period 123 129 618 624 O

Plasma 0 6 625 631 B-clinical_variable
oxalate 7 14 632 639 I-clinical_variable
concentration 15 28 640 653 I-clinical_variable
≥10 29 32 654 657 O
μmol 33 37 658 662 I-lower_bound
/ 37 38 662 663 I-lower_bound
L 38 39 663 664 I-lower_bound
in 40 42 665 667 I-lower_bound
total 43 48 668 673 I-lower_bound
plasma 49 55 674 680 I-lower_bound
oxalate 56 63 681 688 I-lower_bound

Pregnant 0 8 689 697 B-pregnancy
women 9 14 698 703 B-gender
( 15 16 704 705 O
or 16 18 705 707 O
women 19 24 708 713 O
who 25 28 714 717 O
are 29 32 718 721 O
planning 33 41 722 730 B-pregnancy
to 42 44 731 733 I-pregnancy
become 45 51 734 740 I-pregnancy
pregnant 52 60 741 749 I-pregnancy
) 60 61 749 750 O

The 0 3 751 754 O
Schwartz 4 12 755 763 O
formula 13 20 764 771 O
will 21 25 772 776 O
be 26 28 777 779 O
used 29 33 780 784 O
to 34 36 785 787 O
estimate 37 45 788 796 O
GFR 46 49 797 800 B-clinical_variable
for 50 53 801 804 O
children 54 62 805 813 O

The 0 3 814 817 O
existence 4 13 818 827 O
of 14 16 828 830 O
secondary 17 26 831 840 B-chronic_disease
hyperoxaluria 27 40 841 854 I-chronic_disease
, 40 41 854 855 O
e.g. 42 46 856 860 O
hyperoxaluria 47 60 861 874 O
due 61 64 875 878 O
to 65 67 879 881 O
bariatric 68 77 882 891 B-treatment
surgery 78 85 892 899 I-treatment
or 86 88 900 902 O
chronic 89 96 903 910 O
gastrointestinal 97 113 911 927 B-chronic_disease
diseases 114 122 928 936 I-chronic_disease
such 123 127 937 941 O
as 128 130 942 944 O
cystic 131 137 945 951 B-chronic_disease
fibrosis 138 146 952 960 I-chronic_disease
, 146 147 960 961 O
chronic 148 155 962 969 O
inflammatory 156 168 970 982 B-chronic_disease
bowel 169 174 983 988 I-chronic_disease
disease 175 182 989 996 I-chronic_disease
and 183 186 997 1000 O
short 187 192 1001 1006 B-chronic_disease
- 192 193 1006 1007 I-chronic_disease
bowel 193 198 1007 1012 I-chronic_disease
syndrome 199 207 1013 1021 I-chronic_disease

Use 0 3 1022 1025 O
of 4 6 1026 1028 O
antibiotics 7 18 1029 1040 B-treatment
to 19 21 1041 1043 O
which 22 27 1044 1049 O
O. 28 30 1050 1052 O
formigenes 31 41 1053 1063 O
is 42 44 1064 1066 O
sensitive 45 54 1067 1076 O
, 54 55 1076 1077 O
including 56 65 1078 1087 O
current 66 73 1088 1095 O
antibiotic 74 84 1096 1106 O
use 85 88 1107 1110 O
, 88 89 1110 1111 O
or 90 92 1112 1114 O
antibiotics 93 104 1115 1126 O
use 105 108 1127 1130 O
within 109 115 1131 1137 O
14 116 118 1138 1140 B-upper_bound
days 119 123 1141 1145 I-upper_bound
of 124 126 1146 1148 O
initiating 127 137 1149 1159 O
study 138 143 1160 1165 O
medication 144 154 1166 1176 O

Women 0 5 1177 1182 B-gender
of 6 8 1183 1185 O
childbearing 9 21 1186 1198 O
potential 22 31 1199 1208 O
who 32 35 1209 1212 O
are 36 39 1213 1216 O
not 40 43 1217 1220 B-contraception_consent
using 44 49 1221 1226 I-contraception_consent
adequate 50 58 1227 1235 I-contraception_consent
contraceptive 59 72 1236 1249 I-contraception_consent
precautions 73 84 1250 1261 I-contraception_consent

female 0 6 1262 1268 B-gender
patients 7 15 1269 1277 I-gender

